Table 2. Results of uni- and multivariate analysis (Cox proportional hazard model) showing correlation of RFS with clinicopathological factors in patients with breast cancer (nCounter validation cohort).
| Variable | Univariate | ||
|---|---|---|---|
| HR | 95% CI | p value | |
| TP53 status by signature (versus wild type) | 4.94 | 1.57–15.5 | 0.003 |
| pStage (versus Stage I) | 3.94 | 1.11–13.9 | 0.018 |
| Node (versus negative) | 3.49 | 1.24–9.82 | 0.017 |
| Pathological tumor size (versus T1) | 1.68 | 0.61–4.64 | 0.322 |
| Grade (versus 1–2) | 1.51 | 0.54–4.26 | 0.439 |
| ER (versus positive) | 1.68 | 0.60–4.72 | 0.338 |
| PgR (versus positive) | 2.47 | 0.84–7.24 | 0.088 |
| HER2 (versus negative) | 1.54 | 0.35–6.80 | 0.590 |
| Adjuvant chemotherapy (versus non-therapy) | 1.39 | 0.50–3.82 | 0.529 |
| Adjuvant endocrinetherapy (versus non-therapy) | 0.84 | 0.29–2.45 | 0.747 |
| Variable | Multivariate | ||
| HR | 95% CI | p value | |
| TP53 status by signature (versus wild type) | 4.2 | 1.33–13.3 | 0.015 |
| pStage (versus Stage I) | 3.15 | 0.88–11.3 | 0.078 |
Abbreviations: pStage, pathological stage; Node, lymph node metastasis; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor type 2; HR, hazard ratio;CI, confidence interval.